Acute exacerbations of idiopathic pulmonary fibrosis
…, G Raghu, J Roman, JH Ryu, DA Zisman… - American journal of …, 2007 - atsjournals.org
… (C, D) HRCT images through the right upper and lower lung of the same patient during an
acute exacerbation of IPF show new, extensive ground-glass abnormality superimposed on …
acute exacerbation of IPF show new, extensive ground-glass abnormality superimposed on …
Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches
Idiopathic pulmonary fibrosis (IPF), also termed cryptogenic fibrosing alveolitis, is a
clinicopathological syndrome characterised by cough, exertional dyspneoa, basilar crackles, a …
clinicopathological syndrome characterised by cough, exertional dyspneoa, basilar crackles, a …
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general …
…, D Zisman, H Peleg, D Paran, D Levartovsky… - Annals of the …, 2021 - ard.bmj.com
Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic.
Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with …
Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with …
Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease
…, VA Ferrari, MSJ Sutton, DA Zisman… - American journal of …, 2003 - atsjournals.org
Doppler echocardiography is commonly used to estimate systolic pulmonary artery pressure
and to diagnose pulmonary hypertension, but data relating to its utility in patients with …
and to diagnose pulmonary hypertension, but data relating to its utility in patients with …
[HTML][HTML] Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination
…, M Eltity, N Hijazi, A Haddad, M Elias, D Zisman… - Vaccines, 2021 - mdpi.com
Background: Infectious diseases and vaccines can occasionally cause new-onset or flare of
immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 …
immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 …
Drug-induced pneumonitis: the role of methotrexate.
DA Zisman, WJ McCune, G Tino… - … , Vasculitis, and Diffuse …, 2001 - europepmc.org
Methotrexate (MTX) is a folate antagonist used in several chronic inflammatory and neoplastic
conditions. Pulmonary toxicity occurs in 0.5% to 14% of patients receiving low-dose MTX. …
conditions. Pulmonary toxicity occurs in 0.5% to 14% of patients receiving low-dose MTX. …
Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series
V Furer, D Zisman, A Kibari, D Rimar, Y Paran… - …, 2021 - academic.oup.com
Objectives As global vaccination campaigns against COVID-19 disease commence, vaccine
safety needs to be closely assessed. The safety profile of mRNA-based vaccines in patients …
safety needs to be closely assessed. The safety profile of mRNA-based vaccines in patients …
Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease
B Mehrad, MD Burdick, DA Zisman, MP Keane… - Biochemical and …, 2007 - Elsevier
Fibrotic interstitial lung diseases are illnesses of unknown cause characterized by progressive
decline in lung function. Fibrocytes are bone marrow-derived, circulating progenitor cells …
decline in lung function. Fibrocytes are bone marrow-derived, circulating progenitor cells …
[PDF][PDF] Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double‐blind, placebo …
…, V Shobha, Z Sthoeger, D Zisman… - Arthritis & …, 2017 - Wiley Online Library
Objective Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling
without substantial reductions in the number of B cells. The aim of this study was to report …
without substantial reductions in the number of B cells. The aim of this study was to report …
[HTML][HTML] Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen‐week results from a phase III randomized, double‐blind …
…, R Xavier, A Ximenes, D Zisman - Arthritis & …, 2019 - Wiley Online Library
Objective To investigate the efficacy and safety of ixekizumab in patients with active radiographic
axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 …
axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 …